1 / 18

The Case for Anika Therapeutics Inc.

Firm Summary. Woburn, MA with 82 employees Biotechnology industry Market cap of 100.82 MProduces and commercializes HA products for tissue protection/healing/repairOsteoarthritis (humans/horses), post-surgery applications, cosmetic tissue augmentationProducts sold through representatives / dist

mattox
Download Presentation

The Case for Anika Therapeutics Inc.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. The Case for Anika Therapeutics Inc. Harvard Financial Analysts Club – Healthcare Group

    2. Firm Summary Woburn, MA with 82 employees Biotechnology industry Market cap of 100.82 M Produces and commercializes HA products for tissue protection/healing/repair Osteoarthritis (humans/horses), post-surgery applications, cosmetic tissue augmentation Products sold through representatives / distributors

    3. Porter’s Five Forces Rivalry Top 11 account for 65% of industry sales ~350 US-listed public biotech companies Allergan (botox) Buyer Power - weak Few substitutes Demographics – aging population Supplier Power - strong Control over production process

    4. Porter’s Five Forces Threat of Substitutes Other companies with brand name products Generics Barriers to Entry - High Political and regulatory landscape Low healthcare costs, increase safety Patents (for Anika Therapeutics, expirations from 2009 – 2022)

    5. SWOT Analysis Strengths Strong/steady performer – consistent net income and revenue Strong balance sheet (36 M cash, no debt) 10 yr partnership with DePuy Mitek (J&J subsidiary) CTA approval in Europe / US (market growth: 20%) Weaknesses Small, relatively unknown Lack of diversification in products (e.g. all based on HA)

    6. SWOT Analysis Opportunities Scaling up in size (new HQ in Bedford, MA) International expansion (e.g. in Europe with CTA) Threats Competitors with brand name products Partnerships with distributors (e.g. Galderma Pharma S.A.)

    7. Competitor Analysis – CTA Market

More Related